Christopher M Rausch1, Amy Lynne Taylor, Hayley Ross, Stefan Sillau, D Dunbar Ivy. 1. University of Colorado School of Medicine, Department of Pediatrics CO, USA; Children's Hospital Colorado, Division of Pediatric Cardiology, CO, USA. Electronic address: christopher.rausch@childrenscolorado.org.
Abstract
BACKGROUND: Cardiopulmonary exercise testing is widely used in a variety of cardiovascular conditions. Ventilatory efficiency slope can be derived from submaximal exercise testing. The present study sought to evaluate the relationship between ventilatory efficiency slope and functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. METHODS: Seventy six children and young adults with a diagnosis of pulmonary hypertension (PH) performed 258 cardiopulmonary exercise tests from 2001 to 2011. Each individual PH test was matched to a control test. Ventilatory efficiency slope was compared to traditional measures of functional capacity and disease severity including WHO functional classification, peak oxygen consumption, and invasive measures of pulmonary arterial pressures and pulmonary vascular resistance. RESULTS: Ventilatory efficiency slope was significantly higher in patients with pulmonary arterial hypertension, with an estimated increase of 7.2 for each increase in WHO class (p<0.0001), compared with normal control subjects (38.9 vs. 30.9, p<0.001). Ventilatory efficiency slope correlated strongly with invasive measures of disease severity including pulmonary vascular resistance index (r =0.61), pulmonary artery pressure (r =0.58), mean pulmonary artery pressure/mean aortic pressure ratio (r =0.52), and peak VO2 (r=-0.58). Ventilatory efficiency slope in 12 patients with poor outcomes (9 death, 3 lung transplant), was significantly elevated compared to patients who did not (51.1 vs. 37.9, p<0.001). CONCLUSIONS: Ventilatory efficiency slope correlates well with invasive and noninvasive markers of disease severity including peak VO2, WHO functional class, and catheterization variables in pediatric patients with PH. Ventilatory efficiency slope may be a useful noninvasive marker for disease severity.
BACKGROUND: Cardiopulmonary exercise testing is widely used in a variety of cardiovascular conditions. Ventilatory efficiency slope can be derived from submaximal exercise testing. The present study sought to evaluate the relationship between ventilatory efficiency slope and functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. METHODS: Seventy six children and young adults with a diagnosis of pulmonary hypertension (PH) performed 258 cardiopulmonary exercise tests from 2001 to 2011. Each individual PH test was matched to a control test. Ventilatory efficiency slope was compared to traditional measures of functional capacity and disease severity including WHO functional classification, peak oxygen consumption, and invasive measures of pulmonary arterial pressures and pulmonary vascular resistance. RESULTS: Ventilatory efficiency slope was significantly higher in patients with pulmonary arterial hypertension, with an estimated increase of 7.2 for each increase in WHO class (p<0.0001), compared with normal control subjects (38.9 vs. 30.9, p<0.001). Ventilatory efficiency slope correlated strongly with invasive measures of disease severity including pulmonary vascular resistance index (r =0.61), pulmonary artery pressure (r =0.58), mean pulmonary artery pressure/mean aortic pressure ratio (r =0.52), and peak VO2 (r=-0.58). Ventilatory efficiency slope in 12 patients with poor outcomes (9 death, 3 lung transplant), was significantly elevated compared to patients who did not (51.1 vs. 37.9, p<0.001). CONCLUSIONS: Ventilatory efficiency slope correlates well with invasive and noninvasive markers of disease severity including peak VO2, WHO functional class, and catheterization variables in pediatric patients with PH. Ventilatory efficiency slope may be a useful noninvasive marker for disease severity.
Authors: Gérald Simonneau; Ivan M Robbins; Maurice Beghetti; Richard N Channick; Marion Delcroix; Christopher P Denton; C Gregory Elliott; Sean P Gaine; Mark T Gladwin; Zhi-Cheng Jing; Michael J Krowka; David Langleben; Norifumi Nakanishi; Rogério Souza Journal: J Am Coll Cardiol Date: 2009-06-30 Impact factor: 24.094
Authors: Ross Arena; Carl J Lavie; Richard V Milani; Jonathan Myers; Marco Guazzi Journal: J Heart Lung Transplant Date: 2009-12-06 Impact factor: 10.247
Authors: J Theodore; E D Robin; A J Morris; C M Burke; S W Jamieson; A Van Kessel; E B Stinson; N E Shumway Journal: Chest Date: 1986-01 Impact factor: 9.410
Authors: Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd Journal: Chest Date: 2004-07 Impact factor: 9.410
Authors: Michael Arzt; Martina Harth; Andreas Luchner; Frank Muders; Stephan R Holmer; Friedrich C Blumberg; Günter A J Riegger; Michael Pfeifer Journal: Circulation Date: 2003-04-14 Impact factor: 29.690
Authors: Roland Wensel; Christian F Opitz; Stefan D Anker; Jörg Winkler; Gert Höffken; Franz X Kleber; Rakesh Sharma; Manfred Hummel; Roland Hetzer; Ralf Ewert Journal: Circulation Date: 2002-07-16 Impact factor: 29.690
Authors: Hong-Da Zhang; Zi-Chao Lv; Li-Ting Wang; Alexander Rothman; Tian-Yu Lian; Yang-Yang He; Yan Wu; Allan Lawrie; Maurice Beghetti; Zhi-Cheng Jing Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405
Authors: Paloma Lopes Francisco Parazzi; Fernando Augusto de Lima Marson; Maria Angela Gonçalves de Oliveira Ribeiro; Camila Isabel Santos Schivinski; Jose Dirceu Ribeiro Journal: Dis Markers Date: 2015-05-03 Impact factor: 3.434
Authors: Kristian Brat; Nela Stastna; Zdenek Merta; Lyle J Olson; Bruce D Johnson; Ivan Cundrle Journal: PLoS One Date: 2019-04-23 Impact factor: 3.240